Equities Analysts Issue Forecasts for UTHR FY2027 Earnings

United Therapeutics Corporation (NASDAQ:UTHR) – HC Wainwright reduced their FY2027 earnings estimates for shares of United Therapeutics in a research report issued to clients and investors on Friday, September 5th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings of $28.37 per share for the year, down from their previous forecast of $28.77. HC Wainwright has a “Buy” rating and a $500.00 price objective on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). The firm had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business’s revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.85 earnings per share.

A number of other research firms have also recently commented on UTHR. Morgan Stanley decreased their target price on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, September 4th. Bank of America upped their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. JPMorgan Chase & Co. decreased their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a report on Tuesday, July 8th. Finally, Oppenheimer upped their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Nine research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $429.62.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $403.80 on Monday. The firm has a market capitalization of $18.22 billion, a price-to-earnings ratio of 15.76, a PEG ratio of 6.02 and a beta of 0.62. The company’s 50-day moving average is $312.09 and its two-hundred day moving average is $306.29. United Therapeutics has a 1-year low of $266.98 and a 1-year high of $436.95.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. Chung Wu Investment Group LLC purchased a new stake in shares of United Therapeutics during the second quarter worth approximately $29,000. WealthCollab LLC increased its stake in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. increased its position in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. SVB Wealth LLC purchased a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $32,000. Finally, Geneos Wealth Management Inc. increased its position in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Christopher Causey sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $423.21, for a total value of $1,269,630.00. Following the completion of the transaction, the director owned 4,865 shares of the company’s stock, valued at $2,058,916.65. This trade represents a 38.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $385.21, for a total transaction of $4,237,310.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares of the company’s stock, valued at $14,168,409.01. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 106,181 shares of company stock worth $35,537,239. 10.30% of the stock is currently owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.